Is Sanara MedTech, Inc. overvalued or undervalued?

As of 11 February 2019, the valuation grade for Sanara MedTech, Inc. moved from expensive to risky, indicating a shift in perception regarding its valuation. The company appears to be overvalued given its high Price to Book Value of 7.15 and negative EV to EBIT and EV to EBITDA ratios of -32.29 and -73.36, respectively. Additionally, the Return on Capital Employed (ROCE) stands at -14.81%, and the Return on Equity (ROE) is at -36.01%, further supporting the notion of overvaluation.
In comparison to its peers, CareDx, Inc. has a P/E ratio of -27.90 and EV to EBITDA of -27.82, while AngioDynamics, Inc. shows a P/E ratio of -24.69 and an EV to EBITDA of 226.06, both indicating a challenging environment for Sanara MedTech. The company's stock performance relative to the S&P 500 is not available, but the overall financial metrics suggest a concerning outlook for investors.